Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
S5 - E11.1 - How The Rezdiffra Approval Has Affected How One Clinic Manages MASH Patients
In this initial conversation, Michael Charlton describes some ways that the presence of Rezdiffra has affected practices and procedures in his clinic and shares issues he and his collea…
S5 - E11 - Life With Rezdiffra: Early Impact On MASH Patient Treatment and MASLD Clinical Trials
Michael Charlton joins Jörn Schattenberg, Louise Campbell, and Roger Green for a far-reaching conversation that covers ways Rezdiffra is already impacting MASH patient treatment, exciti…
S5 - E10 - Lessons And Insights On Using Basic EHR Data To Screen For Target MASLD Patients
This episode is a follow-up to Season 4, Episode 5, where we met Tim Jobson. His company, Predictive Health Intelligence (PHI), takes a unique approach to identifying and monitoring MAS…
S5 - E9.6 - From The Vault: An Earlier Look At Screening In The Clinical Care Pathway
This conversation comes from our coverage of The EASL Congress, 2023, when Sven Francque and Ian Rowe joined Jörn Schattenberg and Roger Green to consider primary care screening at the …
S5 - E9.5 - In-Office Screening Post-Rezdiffra: The Importance Of Predictive Biomarkers
This conversation focuses on how the need for biomarkers will evolve in an era of in-office screening and MASH drugs and ends with answers to Roger Green's closing question.
Hannes Hags…
S5 - E9.4 - In-office MASLD Screening and the Clinical Care Pathway
This conversation explores the implications of increased access to economically viable in-office screening, particularly when primary care practices begin to use the new scanning device…
S5 - E9.3 - How Will Increased Access To In-Office Scanning Improve MASLD Therapy:
This conversation centers around the different kinds of impact that in-office scanning can have on MASLD therapy, both in terms of improved prognostics and better overall outcomes.
Roge…
S5 - E9.2 - VCTE Studies Demonstrate That Multiple Nutrition Interventions Can Support MASLD Patients
This conversation explores why different nutrition interventions might help MASLD patients improve their overall liver health and what lessons treaters and researchers can learn from th…
S5 - E9.1 - VCTE As A Prognostic And Therapeutic Tool For MASLD
This conversation focuses on the role of VCTE in diagnosing, staging and treating MASLD patients, both in terms of prognostic ability of VCTE when compared to biopsy and separately as a…
S5 - E9 - Value of VCTE Or Other In-Office MASLD Monitoring
Hannes Hagstrom joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss recent research panelists have conducted. This content-dense conversation focuses initially on the im…
S5 - E8 - Changing Patient Incentives For Participating In MASH Clinical Trials
With Louise Campbell and Jörn Schattenberg both on Easter Week vacations, Fatty Liver Alliance Founder Mike Betel joins Roger Green to continue a brief conversation they began in a post…
S5 - E7.6 - MASLD Patient Advocates' Recommendations for Others after Rezdiffra Approval
So far, this conversation has focused on Rezdiffra approval and its many forms of impact on MASLD patient advocates. This conversation considers their recommendation for others.
The con…
S5 - E7.5 - Will Increasing the Focus on MASH via Rezdiffra Overwhelm the Healthcare System?
This conversation asks what impact Rezdiffra patient education might have on a U.S. healthcare system in which 38% of American adults live with some form of MASLD and 15% live with MASH…
S5 - E7.4 - How MASH patient advocates plan to support Rezdiffra
This conversation focuses on how the role of MASLD patient advocates might change and expand in the aftermath of Rezdiffra being approved.
To Wayne Eskridge, this “raises an entirely n…
S5 - E7.3 - Patient advocacy and the Rezdiffra label
This conversation focuses on the steps that patient advocates took to educate the FDA on what patients wanted in a MASH drug label, in this case for Rezdiffra.
It starts with Jeff McInt…
S5 - E7.1 - Rezdiffra is approved! How patient and their advocates processed the news about the first MASH drug
This conversation focuses on advocates' reactions throughout the day on Thursday, March 14, the day Rezdiffra became the first MASH drug approved in the U.S.
Specifically, panelists dis…
S5 - E7.2 - Identifying the target MASH patients for Rezdiffra
This conversation focuses on two issues: (i) identifying the right target MASH patients for Rezdiffra, and (ii) the extensive Madrigal patient support program for Rezdiffra.
It starts wi…
S5 - E7 - MASLD Patient Advocates Celebrate Rezdiffra and Discuss the Future
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their …
S5 - E6.6 - Closing Question From The Episode On Rezdiffra, The First MASH Drug
As the conversation wound down, Roger Green offered panelists to address any issue pertaining to Rezdiffra, the first MASH drug, that had not come up in the hour-long conversation.
The …
S5 - E6.5 - BioPharma Industry Takeaways ForBioPharma Industry Takeaways From The Rezdiffra Launch The Rezdiffra Launch
This conversation revolves around one question: "What lessons should the BioPharma industry take from the launch of Rezdiffra?" Answers revolve largely around clinical trial design and,…